Medpace Stock Rises on Strong Q2 Results, Boosting CRO Sector
Shares of Medpace Holdings surged over 15% following better-than-expected second-quarter financial results and full-year guidance. The positive performance also lifted the broader contract research organization (CRO) sector as investors reacted to the upbeat report.
Tickers: $MEDP
Topics: Biotech Contract Research Organizations (CRO) Pharmaceuticals Stock Market Reaction